Market research
ACET Adicet Bio Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 84M
- P/E ratio
- Not available
- Analyst target
- 33.1667
- Dividend yield
- Not available
- Beta
- 1.59
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US0070022076
- Market cap
- 84M
- P/E ratio
- Not available
- Analyst target
- 33.1667
- Dividend yield
- Not available
- Beta
- 1.59
About
About Adicet Bio Inc
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ACET discussion.
5 years, 4 months ago
From a valuation standpoint, the stock is 482.8% more expensive than other stocks from the Other sector with a price to sales ratio of 5.4.
Based on the above factors, Adicet Bio, Inc gets an overall score of 0/5.